Changes of the Neuronal Activity in the Subthalamic Nucleus Under Remifentanil Sedation During Stereotactic Electrode Implantation
|ClinicalTrials.gov Identifier: NCT00588926|
Recruitment Status : Unknown
Verified December 2007 by Hadassah Medical Organization.
Recruitment status was: Active, not recruiting
First Posted : January 9, 2008
Last Update Posted : January 9, 2008
Deep brain stimulation is commonly used for the treatment of movement disorders. Electrode positioning is usually performed under local anesthesia in fully awake patients. The procedure is uncomfortable to the patients who has to remain motionless during the whole surgery. Previous reports of electrode positioning under general anesthesia was found to be less accurate. This result was probably due to the effect of the anesthetics on the electrical activity of the basal ganglia.
The purpose of this study is to detect possible changes in the electrical activity of the basal ganglia related to remifentanil sedation. electrical activity of single neurons will be recorded before, during and after sedation.
|Condition or disease||Intervention/treatment||Phase|
|Movement Disorders Effect of Remifentanil||Drug: Remifentanil||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
The patients get a period of sedation with remifentanil, before, during and after which, the changes in the electrical activity of the Basal Ganglia is recorded.
After the mapping electrode is in situ, recording of baseline electrical activity is done for two-three minutes and an infusion of Remifentanil, 0.1 microgram per kilogram per minute is started. This procedure continues for a few minutes until the patient is sedated and then the infusion is stopped and the patient allowed to recover. The recordings continue during the whole procedure.
- Electrical activity in the basal ganglia [ Time Frame: During the experiment ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00588926
|Principal Investigator:||Dan Eimerl, MD||Hadassah Medical Organization|